Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|13|1|37-44

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.13, Iss.1, 2018-01, pp. : 37-44

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The ABC's of dopamine receptor partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15‐min challenge to sort these agents out

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 11, 2015-11 ,pp. : 1211-1220

John Wiley & Sons Inc

Access to resources Recommend Favorite

Brexpiprazole shows efficacy in treating acute exacerbation of schizophrenia

By  

THE BROWN UNIVERSITY PSYCHOPHARMACOLOGY UPDATE, Vol. 26, Iss. 8, 2015-08 ,pp. : 1-6

John Wiley & Sons Inc

Access to resources Recommend Favorite

Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 13, 2015-11 ,pp. : 1859-1860

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative partial agonist activity of β‐adrenoceptor antagonists

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 45, Iss. 2, 1972-06 ,pp. : 382-384

John Wiley & Sons Inc

Access to resources Recommend Favorite

Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole

By Albrecht Stefan   Buerger Erich  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2977-2987

Informa Healthcare

Access to resources Recommend Favorite